FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149786525> ?p ?o ?g. }

• W3149786525 endingPage "226" @default.
• W3149786525 startingPage "217" @default.
• W3149786525 abstract "Patients with peripheral artery disease (PAD) treated with lower extremity revascularization are at increased risk of major atherothrombotic vascular events (acute limb ischemia (ALI), major non-traumatic lower-limb amputation, myocardial infarction (MI), ischemic stroke, and cardiovascular (CV)-related death). This study assessed the incidence of major atherothrombotic vascular events, venous thromboembolism (VTE) events and rates of subsequent lower extremity revascularizations in the real-world among patients with PAD after revascularization.Patients aged ≥50 years with PAD who underwent peripheral revascularization were identified from Optum Clinformatics Data Mart claims database (Q1/2014-Q2/2019). The first lower extremity revascularization after PAD diagnosis was defined as index date. Incidence rates of major atherothrombotic vascular events (i.e., composite of ALI, major non-traumatic lower-limb amputation, MI, ischemic stroke, and CV-related death) and VTE were assessed during follow-up as the number of events divided by patient-years of observation (censored at the first event). Rates of subsequent revascularizations and VTE were estimated overall and compared between patients with major atherothrombotic vascular events and those without.Of the 38,439 patients included, 6,675 (17.4%) had a major atherothrombotic vascular event during a median follow-up of 1.0 year. The composite major atherothrombotic vascular and VTE incidence rates were 13.81/100 patient years and 1.77/100 patient years, respectively, and 40.2% of patients experienced subsequent revascularizations. Patients with a post-revascularization major atherothrombotic vascular event had significantly higher rates of subsequent revascularizations (64.6% vs. 35.1%, standardized difference [SD] ≥10%) and VTE (4.6% vs. 2.1%, SD ≥10%) versus those without.One-in-six PAD patients aged ≥50 years who underwent peripheral revascularization experienced a major atherothrombotic vascular event within one year, and consequently, experienced higher rates of subsequent revascularizations compared with those without a major atherothrombotic vascular event post-revascularization. These findings highlight the need to improve strategies to prevent major atherothrombotic vascular events after revascularization." @default.
• W3149786525 created "2021-04-13" @default.
• W3149786525 creator A5006728583 @default.
• W3149786525 creator A5017834828 @default.
• W3149786525 creator A5019269759 @default.
• W3149786525 creator A5028837377 @default.
• W3149786525 creator A5042603671 @default.
• W3149786525 creator A5047559786 @default.
• W3149786525 creator A5054781690 @default.
• W3149786525 creator A5068623275 @default.
• W3149786525 creator A5076746946 @default.
• W3149786525 creator A5090903599 @default.
• W3149786525 date "2021-08-01" @default.
• W3149786525 modified "2023-09-24" @default.
• W3149786525 title "Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization" @default.
• W3149786525 cites W1970904477 @default.
• W3149786525 cites W1979084017 @default.
• W3149786525 cites W2049491523 @default.
• W3149786525 cites W2078178450 @default.
• W3149786525 cites W2121656227 @default.
• W3149786525 cites W2143326022 @default.
• W3149786525 cites W2295484744 @default.
• W3149786525 cites W2404680446 @default.
• W3149786525 cites W2515785929 @default.
• W3149786525 cites W2556919357 @default.
• W3149786525 cites W2609833758 @default.
• W3149786525 cites W2662488897 @default.
• W3149786525 cites W2888053719 @default.
• W3149786525 cites W2902433994 @default.
• W3149786525 cites W2922040573 @default.
• W3149786525 cites W2947016149 @default.
• W3149786525 cites W2975859535 @default.
• W3149786525 cites W2991282332 @default.
• W3149786525 cites W3004033224 @default.
• W3149786525 cites W3013428853 @default.
• W3149786525 cites W3102193847 @default.
• W3149786525 doi "https://doi.org/10.1016/j.avsg.2021.02.025" @default.
• W3149786525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33819600" @default.
• W3149786525 hasPublicationYear "2021" @default.
• W3149786525 type Work @default.
• W3149786525 sameAs 3149786525 @default.
• W3149786525 citedByCount "4" @default.
• W3149786525 countsByYear W31497865252021 @default.
• W3149786525 countsByYear W31497865252022 @default.
• W3149786525 countsByYear W31497865252023 @default.
• W3149786525 crossrefType "journal-article" @default.
• W3149786525 hasAuthorship W3149786525A5006728583 @default.
• W3149786525 hasAuthorship W3149786525A5017834828 @default.
• W3149786525 hasAuthorship W3149786525A5019269759 @default.
• W3149786525 hasAuthorship W3149786525A5028837377 @default.
• W3149786525 hasAuthorship W3149786525A5042603671 @default.
• W3149786525 hasAuthorship W3149786525A5047559786 @default.
• W3149786525 hasAuthorship W3149786525A5054781690 @default.
• W3149786525 hasAuthorship W3149786525A5068623275 @default.
• W3149786525 hasAuthorship W3149786525A5076746946 @default.
• W3149786525 hasAuthorship W3149786525A5090903599 @default.
• W3149786525 hasConcept C120665830 @default.
• W3149786525 hasConcept C121332964 @default.
• W3149786525 hasConcept C126322002 @default.
• W3149786525 hasConcept C127413603 @default.
• W3149786525 hasConcept C141071460 @default.
• W3149786525 hasConcept C164705383 @default.
• W3149786525 hasConcept C2776204877 @default.
• W3149786525 hasConcept C2777466421 @default.
• W3149786525 hasConcept C2779464278 @default.
• W3149786525 hasConcept C2780645631 @default.
• W3149786525 hasConcept C2781099653 @default.
• W3149786525 hasConcept C500558357 @default.
• W3149786525 hasConcept C61511704 @default.
• W3149786525 hasConcept C71924100 @default.
• W3149786525 hasConcept C78519656 @default.
• W3149786525 hasConceptScore W3149786525C120665830 @default.
• W3149786525 hasConceptScore W3149786525C121332964 @default.
• W3149786525 hasConceptScore W3149786525C126322002 @default.
• W3149786525 hasConceptScore W3149786525C127413603 @default.
• W3149786525 hasConceptScore W3149786525C141071460 @default.
• W3149786525 hasConceptScore W3149786525C164705383 @default.
• W3149786525 hasConceptScore W3149786525C2776204877 @default.
• W3149786525 hasConceptScore W3149786525C2777466421 @default.
• W3149786525 hasConceptScore W3149786525C2779464278 @default.
• W3149786525 hasConceptScore W3149786525C2780645631 @default.
• W3149786525 hasConceptScore W3149786525C2781099653 @default.
• W3149786525 hasConceptScore W3149786525C500558357 @default.
• W3149786525 hasConceptScore W3149786525C61511704 @default.
• W3149786525 hasConceptScore W3149786525C71924100 @default.
• W3149786525 hasConceptScore W3149786525C78519656 @default.
• W3149786525 hasFunder F4320315730 @default.
• W3149786525 hasFunder F4320317188 @default.
• W3149786525 hasLocation W31497865251 @default.
• W3149786525 hasLocation W31497865252 @default.
• W3149786525 hasOpenAccess W3149786525 @default.
• W3149786525 hasPrimaryLocation W31497865251 @default.
• W3149786525 hasRelatedWork W1978164495 @default.
• W3149786525 hasRelatedWork W2063036634 @default.
• W3149786525 hasRelatedWork W2089259171 @default.
• W3149786525 hasRelatedWork W2098520058 @default.
• W3149786525 hasRelatedWork W2133914046 @default.
• W3149786525 hasRelatedWork W2313378421 @default.

• next